Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transdermal Drug Delivery Systems

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...

Birth Control Methods

Birth Control Methods

Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although vasectomy...

Intrauterine Drug Delivery Systems

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Drug Delivery: Miscellaneous Routes

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...

Hormonal Regulation of the Menstrual Cycle

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Evolving Role of Midwives as Laborists.

Journal of midwifery & women's health·2015

Same author

Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women.

Breast cancer research : BCR·2013

Same author

Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.

BMC cancer·2013

Same author

Estrogen-related genes and their contribution to racial differences in breast cancer risk.

Cancer causes & control : CCC·2012

Same author

Oral contraceptive formulation and risk of breast cancer.

Contraception·2011

Same author

Fifty years of "the pill": risk reduction and discovery of benefits beyond contraception, reflections, and forecast.

Toxicological sciences : an official journal of the Society of Toxicology·2011

Search research articles

Related Experiment Videos

Transdermal hormonal contraception: benefits and risks.

Ronald T Burkman¹

¹Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, MA 01199, USA. rtb@bhs.org

American Journal of Obstetrics and Gynecology

|August 11, 2007

Summary

This summary is machine-generated.

Transdermal drug delivery systems offer diverse therapeutic options. While clinical data support the contraceptive patch

Related Experiment Videos

Area of Science:

Pharmacology and Drug Delivery
Reproductive Health
Clinical Therapeutics

Background:

Transdermal drug delivery systems (TDDS) have been utilized in the US for over two decades.
Numerous TDDS products are FDA-approved for various conditions, including pain, hypertension, and hormone therapy.
The contraceptive patch represents a significant advancement in non-oral contraception.

Purpose of the Study:

To review the history and applications of transdermal drug delivery systems.
To evaluate the efficacy and safety profile of the contraceptive patch.
To address concerns and regulatory actions related to the contraceptive patch.

Main Methods:

Review of clinical data and FDA approvals for transdermal products.
Analysis of epidemiologic studies investigating venous thromboembolism risk with the contraceptive patch.
Examination of revised product labeling and clinical recommendations.

Main Results:

Over 35 transdermal patch products are approved for diverse indications.
Clinical data confirm the contraceptive patch's efficacy and safety.
Concerns about estrogen levels and venous thromboembolism led to further studies and labeling updates.

Conclusions:

Transdermal drug delivery systems provide a valuable alternative for medication administration.
The contraceptive patch, despite past concerns, remains a viable option for select patients.
Ongoing research and regulatory oversight ensure the safe and effective use of TDDS.